Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 16, 2025, titled "Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery".
Press Release Apr 16 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding its investment in Feldan Therapeutics to enhance intracellular drug delivery innovation. The investment aims to support the development of treatments for conditions like basal cell carcinoma and respiratory diseases using Feldan's proprietary technology. Dr. Sharvil Patel of Zydus emphasized the commitment to advancing novel therapeutics to improve patient quality of life through this partnership. Zynext Ventures, the investment arm of Zydus, will provide strategic guidance and financial support to Feldan.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Apr 11 2025
- Press Release Mar 18 2025
- Press Release Mar 16 2025
- Press Release Mar 14 2025
- Press Release Mar 12 2025
Later from Zydus Lifesciences
- Press Release Apr 17 2025
- ITC Reversal Of Common ITC U/s17(2) Required In Relation To Activity Of Subscription And Redemption Of Mutual Funds
- Press Release Apr 25 2025
- Press Release Apr 26 2025
- Press Release Apr 30 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences